ERBB2 and breast carcinoma: As we can see in Figure S1 and as previously reported by our group [24], the acquisition of resistance to trastuzumab in these four HER2-positive breast cancer cell lines was associated with an increase in the amounts of p-ERK, p-AKT and p-S6, suggesting a higher level of activation of their PI3K and MAPK pathways and a plausible association with mechanisms of resistance generation in these cell line models.